Microbix Biosystems Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBXBF research report →
Companymicrobix.com
Microbix Biosystems Inc. , a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.
- CEO
- Cameron L. Groome
- IPO
- 2021
- Employees
- 100
- HQ
- Mississauga, ON, CA
Price Chart
Valuation
- Market Cap
- $23.29M
- P/E
- -5.45
- P/S
- 2.11
- P/B
- 1.24
- EV/EBITDA
- -9.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 42.49%
- Op Margin
- -33.32%
- Net Margin
- -38.62%
- ROE
- -21.02%
- ROIC
- -15.19%
Growth & Income
- Revenue
- $18.61M · -26.71%
- Net Income
- $-2,248,992 · -163.89%
- EPS
- $-0.02 · -162.79%
- Op Income
- $-1,576,154
- FCF YoY
- -136.00%
Performance & Tape
- 52W High
- $0.29
- 52W Low
- $0.15
- 50D MA
- $0.18
- 200D MA
- $0.18
- Beta
- 0.81
- Avg Volume
- 6.24K
Get TickerSpark's AI analysis on MBXBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MBXBF Coverage
We haven't published any research on MBXBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MBXBF Report →